THE MELANOMA AND NON-MELANOMA SKIN CANCERS STAGING IN A GROUP OF PATIENTS
Abstract:
The staging of skin cancer allows the issuance of the prognosis and the therapeutical concepts
required to maximize the result and to reduce the negative impacts of the inappropriate tumor stage
therapy. Study objectives: assessing the importance of accurate staging of NMSC and MSC as a
prognosis factor. Material and methods: during 2007 – 2010 we conducted a prospective study of 385
patients with non-melanoma skin cancer (NMSC) and melanoma skin cancer (MSC) hospitalized in the
Clinics of Dermatology and Oncology. In this patients we make the staging according to AJCC 2010
classification. Result and discussions. The NMSC was mostly diagnosed in the stage I (88,98% from
BCC and 87,82% from SCC). Nearly half of MSC were diagnosed in late-stage disease (49,40% from
MM was in the stage III and IV). By analyzing the Breslow index (BI) we noticed that BI with the worst
prognosis (over 4mm) was the most common (36,14%). Conclusions. Our results support the idea of
continued growth of the MM aggressiveness by late-stage diagnosis with more reserved prognosis.
full text article in English (.EN) |